This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Psychopharmacology  • Schizophrenia  • Randomized Controlled Trial  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Jim Mintz, PhD; Alex Kopelowicz, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS)¹ of the relative effectiveness of first (FGA)- and second (SGA)-generation antipsychotic treatments of schizophrenia reports negative findings, concluding that "there is no disadvantage across 1 year . . . in using FGAs. . . . "^1(p1079) In one commentary,² Lieberman calls the findings of CUtLASS and the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study "virtually identical," clearly referring to what he calls the "sobering"^2(p1071) conclusion that "these studies found few differences in effectiveness between first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs). . . . "^2(p1069) In another commentary,³ Rosenheck writes that CUtLASS "echoes" CATIE, which "similarly, found no significant differences in time to all-cause discontinuation, the primary outcome. . . . "^2(p1075)

These 2 major studies differed in the measure of drug "effectiveness." CUtLASS used "quality of life," and CATIE used all-cause discontinuation. As it happens, CUtLASS also presents data on all-cause discontinuation in the . . . [Full Text of this Article]

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Comparative Effectiveness of Antipsychotic Drugs: A Commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
Jeffrey A. Lieberman
Arch Gen Psychiatry. 2006;63(10):1069-1072.
EXTRACT | FULL TEXT  

Outcomes, Costs, and Policy Caution: A Commentary on the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
Robert A. Rosenheck
Arch Gen Psychiatry. 2006;63(10):1074-1076.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Randomized Controlled Trials for Schizophrenia: Study Designs Targeted to Distinct Goals
Stroup and Geddes
Schizophr Bull 2008;34:266-274.
ABSTRACT | FULL TEXT  

Rapid tranquillisation in emergency psychiatric settings
Andrade
BMJ 2007;335:835-836.
FULL TEXT